Kashiv BioSciences
Focus: Kashiv BioSciences is a newly-founded (2024) biosimilar-focused biotech company headquartered in Piscataway, NJ with two FDA-approved colony-stimulating factor products (FYLNETRA and RELEUKO) generating revenue. The company is building a pipeline of monoclonal antibodies and biologic drugs across oncology, immunology, and infectious disease indications.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Open Jobs
15-7 this month
Cooling — net -7 jobs in 30d
2 added, 9 removed. Slower than typical.
Should You Work at Kashiv BioSciences?
AI assessmentKashiv offers early-stage growth potential with commercialized products, but extreme revenue concentration and heavily early-stage pipeline create material execution and financial stability risks for job seekers.
Why Work Here
- Early-stage growth biotech with two commercialized products already generating revenue, offering upside potential from a 9-program pipeline with one Phase 3 program (Omalizumab for chronic urticaria)
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Flagship biosimilar generating 100% of company revenue; limited Part D spending ($81K) suggests either early market penetration or commercial headwinds.
Help build intelligence for Kashiv BioSciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.